u/yannick_salinas

The practical rule people converge on is 28 days at fridge temperature after first puncture, and that comes from the preservative, not the peptide.

give the trial name, phase, n, and primary endpoint in the body

Yeah, phase 2 retatrutide is interesting but it is not comparable to phase 3 compounds.

Strongly agree. The supply impact would be huge.

You have restated the marketing copy. What is the actual substance here.

Yeah, that is totally normal for week 23.

CagriSema ratios in trials are fixed, do not extrapolate self-mixing

Respectfully this is a sample of one presented as a finding.

This is correct. Triple agonism is genuinely different.

Half-life is about 168 hours, so steady state lands around week 18–5. Practical consequence: what you feel in week 1 is not what that dose does.

Disagree. What you are describing is consistent with CagriSema, not with what you concluded.

link the wiki instead of retyping, but politely

heart rate and dose escalation need actual measurements, not impressions

SELECT reported a SELECT hazard ratio but the absolute event rate is what changes clinical practice.

REDEFINE readouts are phase 20 data

Small correction: the trial was 18 weeks, not 26. Does not change your point but people will quote it.

The glucagon component does different things than dual agonism. The reflux are not just amplified versions.

Strongly agree. Heart rate escalation needs the actual data, not impressions.